Analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the stock.
Bio-Path Stock Up 4.8 %
Bio-Path stock opened at $0.91 on Friday. The stock has a 50-day simple moving average of $1.00 and a 200 day simple moving average of $1.67. Bio-Path has a 12-month low of $0.80 and a 12-month high of $12.43.
Bio-Path (NASDAQ:BPTH – Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the prior year, the firm earned ($10.60) earnings per share. Sell-side analysts anticipate that Bio-Path will post -6.2 EPS for the current year.
Institutional Trading of Bio-Path
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Recommended Stories
- Five stocks we like better than Bio-Path
- What Do S&P 500 Stocks Tell Investors About the Market?
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Roth IRA Calculator: Calculate Your Potential Returns
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Best Aerospace Stocks Investing
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.